Drug intelligence / Profile preview

RespiSure

Development stage: Unknown
Lead developer: Zoetis
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

RespiSure is a veterinary swine vaccine consisting of a whole-cell inactivated Mycoplasma hyopneumoniae bacterin formulated with the Amphigen adjuvant to enhance and prolong the immune response. It is used in pigs and sows as an aid in preventing or reducing the severity of enzootic (chronic) pneumonia caused by Mycoplasma hyopneumoniae, a key pathogen in the porcine respiratory disease complex. By inducing active immunity against M. hyopneumoniae, RespiSure reduces lung colonization and shedding, thereby helping to control clinical disease and improve herd respiratory health and performance.

Brand names: RespiSure

Beyond the preview

Go deeper on RespiSure.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RespiSure.

Explore the full profile